3SBio (TRSBF) Stock Price, News & Analysis

Company Overview

3SBio Inc. is a China-based biopharmaceutical company primarily engaged in the research, development, manufacturing and commercialization of proprietary biologic products. Headquartered in Taizhou, Jiangsu Province, the company focuses on therapeutic proteins, vaccines and diagnostic reagents tailored to address major therapeutic areas such as oncology supportive care, metabolic disorders and cardiovascular diseases.

The company’s marketed portfolio includes recombinant human thrombopoietin for chemotherapy-induced thrombocytopenia, recombinant streptokinase for acute myocardial infarction, insulin analogs for diabetes management and a range of hepatitis B vaccines. In addition to its core biologics, 3SBio manufactures colony stimulating factors and growth hormones, serving both hospital and community healthcare channels. The company also operates a dedicated diagnostics business that produces enzyme-linked immunosorbent assay (ELISA) kits and rapid test strips for infectious diseases.

Founded in 1999 as a spin-off of the Shanghai Institute of Biochemistry and Cell Biology, 3SBio has built an integrated R&D platform that spans discovery, preclinical development, clinical trials and commercial manufacturing. The company holds Good Manufacturing Practice (GMP) certification for its facilities and maintains strategic partnerships and licensing agreements with multinational pharmaceutical firms to co-develop and market select biologic candidates both domestically and internationally.

3SBio’s products are distributed across China through a multi-tier sales network covering more than 30 provinces and municipalities. The company has also expanded its presence in Asia, Europe and Latin America via export channels and local collaborations. Supported by a leadership team with extensive experience in biotechnology and pharmaceutical commercialization, 3SBio continues to advance its pipeline of novel biologics while scaling up its manufacturing capabilities to meet growing global demand.

Key Stats

• Today's Range: $3.72 to $3.72
• 50-Day Range: $0.83 to $3.83
• 52-Week Range: $2.22 to $4.00
• Volume: N/A
• Average Volume: 1,527 shs
• Market Capitalization: N/A
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

TRSBF Stock Analysis - Frequently Asked Questions

How have TRSBF shares performed this year?

3SBio's stock was trading at $0.8279 at the beginning of the year. Since then, TRSBF stock has increased by 349.3% and is now trading at $3.72.

How do I buy shares of 3SBio?

Shares of TRSBF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

• Today: 7/22/2025
• Next Earnings (Estimated): 8/20/2025

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Medical
• Industry: Biotechnology
• Sub-Industry: N/A
• Current Symbol: OTCMKTS:TRSBF
• CIK: N/A
• Web: www.3sbio.com
• Phone: 86 24 2538 6000
• Fax: N/A
• Employees: 5,411
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: N/A
• Free Float: N/A
• Market Cap: N/A
• Optionable: Not Optionable
• Beta: N/A